CD22 and lymphoma: With a DAR of 1.74, epratuzumab-cys-tesirine shows potent and specific in vitro and in vivo activity against different CD22-expressing human lymphoma models (Ramos, Daudi, WSU-DLCL2, and SU-DHL-4), inducing DNA inter-strand cross-linking after a 2-h exposure period.